TABLE 3.

Comparison of serological domains

	A	B	C	D	A versus B	A versus C	B versus C	A versus D	B versus D	C versus D
Patients n	144	56	57	98
Serological domain	91.7	91.1	93	nr	ns	ns	ns
ANA	77.6	48.2	82.4	47.9	<0.0001	ns	0.0001	<0.0001	ns	<0.0001
RF ≥40 IU	13	10.7	7	28.5#	ns	ns	ns	0.0002	0.01	0.0001
ACPA	4.7	10.7	8.8	15.3	ns	ns	ns	0.004	ns	ns
Anti-Sdna	7.2	1.8	5.2	6.2	ns	ns	ns	ns	ns	ns
Anti-Ro/SS-A	16.6	42.9	8.8	18.3	<0.0001	ns	<0.0001	ns	0.001	ns
Anti-La/SS-B	2.9	5.4	1.7	7.1	ns	ns	ns	ns	ns	ns
Anti-RNP	4.9	16.1	0	9.1	0.008	ns	0.001	ns	ns	0.01
Anti-Smith	1.5	8.9	0	4.1	0.01	ns	0.02	ns	ns	ns
Anti-Scl70	3	1.8	5.2	8.1	ns	ns	ns	0.07	ns	ns
Anti-tRNA synthetase	0.7	35.7	15.8	13.2	<0.0001	0.05	0.01	<0.0001	0.001	ns
Anti-PM/Scl		1.8	5.2	nr			ns
Anti-MDA-5		0	0	nr			ns

Data are presented as mean±sd or %, unless otherwise stated. Bold represents the highest significant value. A: Oldham et al. [18]; B: Chartrand et al. [22]; C: Ahmad et al. [23]; D: Ito et al. [24]; ANA: antinuclear antibodies; RF: rheumatoid factor; ACPA: anti-citrullinated protein antibodies; SS: Sjögren syndrome; RNP: ribonucleoprotein; PM/Scl: polymyositis/systemic sclerosis; MDA: melanoma differentiation antigen; nr: not reported; ns: nonsignificant. ^#: RF >60 IU.